Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/133844
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaietti, Maria Francesca-
dc.contributor.authorSimicek, Michal-
dc.contributor.authorAbbasi Asbagh, Layka-
dc.contributor.authorRadaelli, Enrico-
dc.contributor.authorLievens, Sam-
dc.contributor.authorCrowther, Jonathan-
dc.contributor.authorSteklov, Mikhail-
dc.contributor.authorAushev, Vasily N.-
dc.contributor.authorMartínez García, David-
dc.contributor.authorTavernier, Jan-
dc.contributor.authorSablina, Anna A.-
dc.date.accessioned2019-05-24T16:32:29Z-
dc.date.available2019-05-24T16:32:29Z-
dc.date.issued2016-02-08-
dc.identifier.issn1757-4676-
dc.identifier.urihttp://hdl.handle.net/2445/133844-
dc.description.abstractActivation of the RAS oncogenic pathway, frequently ensuing from mutations in RAS genes, is a common event in human cancer. Recent reports demonstrate that reversible ubiquitination of RAS GTPases dramatically affects their activity, suggesting that enzymes involved in regulating RAS ubiquitination may contribute to malignant transformation. Here, we identified the de-ubiquitinase OTUB1 as a negative regulator of RAS mono- and di-ubiquitination. OTUB1 inhibits RAS ubiquitination independently of its catalytic activity resulting in sequestration of RAS on the plasma membrane. OTUB1 promotes RAS activation and tumorigenesis in wild-type RAS cells. An increase of OTUB1 expression is commonly observed in non-small-cell lung carcinomas harboring wild-type KRAS and is associated with increased levels of ERK1/2 phosphorylation, high Ki67 score, and poorer patient survival. Our results strongly indicate that dysregulation of RAS ubiquitination represents an alternative mechanism of RAS activation during lung cancer development-
dc.format.extent16 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherEMBO Press-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.15252/emmm.201505972-
dc.relation.ispartofEMBO Molecular Medicine, 2016, vol. 8, num. 3, p. 288-303-
dc.relation.urihttps://doi.org/10.15252/emmm.201505972-
dc.rightscc-by (c) Baietti, Maria Francesca et al., 2016-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationCisteïna-
dc.subject.classificationPèptids-
dc.subject.classificationMetabolisme-
dc.subject.classificationPatologia-
dc.subject.classificationCàncer de pulmó-
dc.subject.classificationProteïnes ras-
dc.subject.otherCysteine-
dc.subject.otherPeptides-
dc.subject.otherMetabolism-
dc.subject.otherPathology-
dc.subject.otherLung cancer-
dc.subject.otherRas proteins-
dc.titleOTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec676948-
dc.date.updated2019-05-24T16:32:29Z-
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/340941/EU//CYRE-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid26881969-
Appears in Collections:Publicacions de projectes de recerca finançats per la UE
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
676948.pdf1.48 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons